These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 29698196)

  • 1. The State of Cost-Utility Analyses in Asia: A Systematic Review.
    Thorat T; Lin PJ; Neumann PJ
    Value Health Reg Issues; 2015 May; 6():7-13. PubMed ID: 29698196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.
    Neumann PJ; Fang CH; Cohen JT
    Pharmacoeconomics; 2009; 27(10):861-72. PubMed ID: 19803540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth and quality of the cost-utility literature, 1976-2001.
    Neumann PJ; Greenberg D; Olchanski NV; Stone PW; Rosen AB
    Value Health; 2005; 8(1):3-9. PubMed ID: 15841889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changing face of the cost-utility literature, 1990-2012.
    Neumann PJ; Thorat T; Shi J; Saret CJ; Cohen JT
    Value Health; 2015 Mar; 18(2):271-7. PubMed ID: 25773562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analyses of diagnostic laboratory tests: a systematic review.
    Fang C; Otero HJ; Greenberg D; Neumann PJ
    Value Health; 2011 Dec; 14(8):1010-8. PubMed ID: 22152169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence.
    Zhong Y; Lin PJ; Cohen JT; Winn AN; Neumann PJ
    Value Health; 2015 Mar; 18(2):308-14. PubMed ID: 25773567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of Evidence Sources for Health-Related Quality of Life in Cost-Utility Analysis of Pharmaceuticals in Japan.
    Azuma MK; Ikeda S
    Value Health Reg Issues; 2014 May; 3():190-196. PubMed ID: 29702927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the measurement of health utilities in published cost-utility analyses.
    Brauer CA; Rosen AB; Greenberg D; Neumann PJ
    Value Health; 2006; 9(4):213-8. PubMed ID: 16903990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analyses of drug therapies in breast cancer: a systematic review.
    Nerich V; Saing S; Gamper EM; Kemmler G; Daval F; Pivot X; Holzner B
    Breast Cancer Res Treat; 2016 Oct; 159(3):407-24. PubMed ID: 27572551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease.
    Zhou T; Chen Z; Li H; Xie F
    Med Decis Making; 2021 Aug; 41(6):685-692. PubMed ID: 33813938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we better prioritize resources for cost-utility research?
    Neumann PJ; Rosen AB; Greenberg D; Olchanski NV; Pande R; Chapman RH; Stone PW; Ondategui-Parra S; Nadai J; Siegel JE; Weinstein MC
    Med Decis Making; 2005; 25(4):429-36. PubMed ID: 16061895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The adoption of cost-effectiveness acceptability curves in cost-utility analyses.
    Meckley LM; Greenberg D; Cohen JT; Neumann PJ
    Med Decis Making; 2010; 30(3):314-9. PubMed ID: 19773582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of health-state utilities used in cost-effectiveness analyses: a systematic review of published studies in Asia.
    Yang Z; Zeng X; Huang W; Chai Q; Zhao A; Chuang LH; Wu B; Luo N
    Health Qual Life Outcomes; 2023 Jun; 21(1):59. PubMed ID: 37340446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of biopharmaceuticals: a look at the evidence.
    Wilson AW; Neumann PJ
    MAbs; 2012; 4(2):281-8. PubMed ID: 22377753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life.
    Scope A; Bhadhuri A; Pennington B
    Value Health; 2022 Sep; 25(9):1644-1653. PubMed ID: 35339379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic overview of cost-utility assessments in oncology.
    Earle CC; Chapman RH; Baker CS; Bell CM; Stone PW; Sandberg EA; Neumann PJ
    J Clin Oncol; 2000 Sep; 18(18):3302-17. PubMed ID: 10986064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Family Spillover Effects in Pediatric Cost-Utility Analyses.
    Lavelle TA; D'Cruz BN; Mohit B; Ungar WJ; Prosser LA; Tsiplova K; Vera-Llonch M; Lin PJ
    Appl Health Econ Health Policy; 2019 Apr; 17(2):163-174. PubMed ID: 30350218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy, risk and the intrinsic value of diagnostic imaging: a review of the cost-utility literature.
    Otero HJ; Fang CH; Sekar M; Ward RJ; Neumann PJ
    Acad Radiol; 2012 May; 19(5):599-606. PubMed ID: 22342653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses.
    Picavet E; Cassiman D; Simoens S
    J Clin Pharm Ther; 2015 Jun; 40(3):304-7. PubMed ID: 25891411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costing and perspective in published cost-effectiveness analysis.
    Neumann PJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.